MarketPulse

immunogenicity

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Serina Therapeutics Unveils PEG-Free LNP Technology at Industry Summit

Serina's Chief Development Officer to present novel POZ-based lipid nanoparticles that eliminate PEG immunogenicity issues, showing no antibody response in preclinical studies.
PFESERbiotechnologydrug delivery
GlobeNewswire Inc.GlobeNewswire Inc.··Vaxcyte, Inc.

Vaxcyte's 31-Valent Pneumococcal Vaccine Advances to Phase 3 on Strong Clinical Data

Vaxcyte publishes positive Phase 1/2 data for VAX-31, a 31-valent pneumococcal vaccine, and advances to Phase 3 trials with topline results expected Q4 2026.
PCVXPhase 3 clinical trialBreakthrough Therapy Designation